37results about How to "Treat osteoporosis" patented technology

A Chinese medicine in the form of tablet or capsule for treating the climacteric syndrome of woman, osteoporosis, and cardiovascular disease and improving immunity contains proportionally soybean isoflavone, extract of astragalus root, general saponin of gynostemma pentaphyllum, microcrystalline cellulose, cardoxymethyl starch sodium or low-substituted hydroxypropyl cellulose, and magnesium stearate. Its preparing process is also disclosed.

The invention discloses a medicine for promoting fracture healing. The medicine is characterized by being prepared from the following Chinese medicines in part by weight: 6 to 9 parts of Japanese thistle herb, 6 to 9 parts of rhubarb, 2 to 4 parts of cattail pollen, 2 to 4 parts of ground beetle, 2 to 4 parts of Chinese gall, 2 to 4 parts of root of chloranthus japonicus, 6 to 9 parts of herb of rose glorybind, 1 to 3 parts of veratrum nigrum and 1 to 3 parts of bomeol. A preparation method for the medicine comprises the following steps of: adding extracted volatile oil of the cattail pollen and the root of chloranthus japonicus, and ultrafine powder of veratrum nigrum and bomeol into an aqueous extract solution of the Japanese thistle herb, the rhubarb, the ground beetle, the Chinese gall and the rose glorybind, stirring uniformly and concentrating under reduced pressure. Clinical trials prove that the medicine for promoting the fracture healing has the characteristics of good curative effects and higher safety, so the medicine is worth clinical application and popularization.

The invention provides a compound as well as a preparation method and application thereof. The compound has a structure shown as formula (I), and the compound can treat osteoporosis; moreover, by virtue of cell experiments, the compound is discovered to have an effect on promoting the proliferation of osteoblasts; and when the sample concentration is 10mu M, the proliferation rate can reach 11.24 percent.

The invention relates to the field of food processing, in particular to a biological processing method of red dates. According to the method, red date pulp is fermented through monascus, wine-related yeasts and saccharomyces cerevisiae in beer fermentation equipment, solid-liquid separation is conducted after fermented liquor is mature, products in a light phase, a heavy phase and a solid phase are obtained, and production of down-stream products can be conducted respectively. According to the method, the products generated by processing the red dates are completely utilized, and all the nutritious substances contained in the red dates are converted into food efficiently to be absorbed and utilized by a human body.

The invention discloses a three-dimensional printing strontium-containing mesoporous bioglass bracket loaded with soy isoflavone, and belongs to the field of the biomedical material. The bracket is composed of the strontium-containing mesoporous bioglass (Sr-MBG), polycaprolactone (PCL) and soy isoflavone, wherein the quality proportions of the Sr-MBG and PCL are 70% and 30% respectively, and 5% of Ca in the Sr-MBG is replaced by Sr. The soy isoflavone is loaded into the mesoporous of the Sr-MBG, two materials of the Sr-MBG loaded with the soy isoflavone and the PCL are printed to be the cubical biological activity bracket layer by layer by using the three-dimensional printing technology, each layer is formed by crisscrossed perpendicular lines, and the pore formed by the perpendicular lines is a square. The bracket can be applied to the repair and treatment in allusion to the bone defect, has good biocompatibility and better capacity for promoting osteogenesis and can be absorbed and degraded by the living organism. The treatment effect for the bone defect of the osteoporosis patient can be enhanced after the soy isoflavone is loaded, and the bracket is the perfect bracket material for bone tissue engineering.

The present disclosure relates to a new diphosphonate compound, and the method to prepare the above new diphosphonate compound. The new diphosphonate compound exhibits an activity in inhibiting osteoclast equivalent to alendronate sodium, and a higher activity in affecting the proliferation of osteoplast than the positive control compounds, but the positive control exhibits a weaker effect on osteoblast proliferation. In experimental examples, an administration schedule for the diphosphonate compound is provided.